Analyst Ratings For Alexion Pharmaceuticals (NASDAQ:ALXN)
Today, Guggenheim initiated coverage on Alexion Pharmaceuticals (NASDAQ:ALXN) with a Neutral.
There are 13 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Alexion Pharmaceuticals (NASDAQ:ALXN) is Buy with a consensus target price of $164.3571 per share, a potential 28.86% upside.
Some recent analyst ratings include
- 2/22/2019-Alexion Pharmaceuticals (NASDAQ:ALXN) has coverage initiated with a Neutral rating
- 1/22/2019-Alexion Pharmaceuticals (NASDAQ:ALXN) had its Buy rating reiterated by Credit Suisse Group with a $156.00 price target
- 12/30/2018-Alexion Pharmaceuticals (NASDAQ:ALXN) had its Buy rating reiterated by Raymond James
- On 2/14/2019 Daniel Bazarko, CAO, sold 2,000 with an average share price of $126.00 per share and the total transaction amounting to $252,000.00.
- On 12/31/2018 Ludwig Hantson, CEO, sold 3,244 with an average share price of $95.85 per share and the total transaction amounting to $310,937.40.
- On 12/31/2018 Ludwig Hantson, CEO, sold 3,244 with an average share price of $95.85 per share and the total transaction amounting to $310,937.40.
- On 11/28/2018 Indrani Lall Franchini, EVP, sold 2,605 with an average share price of $118.13 per share and the total transaction amounting to $307,728.65.
- On 7/10/2018 Paul J Clancy, CFO, sold 5,241 with an average share price of $131.11 per share and the total transaction amounting to $687,147.51.
- On 6/8/2018 John J Orloff, EVP, sold 2,115 with an average share price of $118.53 per share and the total transaction amounting to $250,690.95.
- On 4/30/2018 Christopher J Coughlin, Director, bought 10,000 with an average share price of $120.79 per share and the total transaction amounting to $1,207,900.00.
About Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; and collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Recent Trading Activity for Alexion Pharmaceuticals (NASDAQ:ALXN)
Shares of Alexion Pharmaceuticals closed the previous trading session at 127,55 −2,29 1,76 % with 1013600 shares trading hands.